RxDoctor Payments DataLook up a doctor →

Peter Dipasco, MD

Surgical Oncology · Saint Louis, MONPI 1659491314

Payments from drug & device makers

$246,626in general payments, 2019–2025

Across 424 payments — averaging $581.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$149K
  • Johnson & Johnson$79K
  • Ethicon Endo-surgery Inc.$12K
  • Histosonics, Inc.$939
  • Regeneron Healthcare Solutions, Inc.$369
  • Hologic Sales And Service, LLC$306
  • plus $4K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medical Device Business Services, Inc.126$149,369
Johnson & Johnson(3 entities)124$79,256
Ethicon Endo-surgery Inc.6$12,358
Histosonics, Inc.5$939
Regeneron Healthcare Solutions, Inc.8$369
Hologic Sales And Service, LLC3$306
Merck13$294
Tempus AI, Inc3$251
AstraZeneca11$235
Daiichi Sankyo Inc.6$219
Intera Oncology, Inc1$175
Stryker1$173
Dilon Technologies, Inc.2$156
Genentech USA, Inc.6$154
Pfizer6$141
Takeda Pharmaceuticals U.S.A., Inc.7$136
AbbVie5$127
Incyte Corporation7$126
Novo Nordisk1$125
Seagen Inc.5$120
Amgen6$109
Novartis6$107
Siemens Medical Solutions USA, Inc.1$106
Lilly USA, LLC4$93
Eisai Inc.4$81
Bayer4$70
Taiho Oncology, Inc.4$69
Myriad Genetic Laboratories, Inc.3$69
Puma Biotechnology, Inc.3$59
Sanofi2$48
Springworks Therapeutics, Inc.2$47
Mirati Therapeutics, Inc.2$42
Sobi, Inc2$41
Kyowa Kirin, Inc.2$41
ADC Therapeutics America, Inc.2$40
Blueprint Medicines Corporation2$39
Servier Pharmaceuticals LLC2$35
Global Blood Therapeutics, Inc.2$32
Galvanize Therapeutics, Inc1$29
ETS Wound Care LLC1$29
Astellas Pharma US Inc1$28
G1 Therapeutics, Inc.1$22
Intuitive Surgical1$22
Beigene USA, Inc.1$22
Medtronic1$22
Blue Earth Diagnostics1$21
Immunogen, Inc.1$20
EMD Serono, Inc.1$20
Octapharma USA, Inc.1$19
AVEO Pharmaceuticals, Inc.1$19
Morphosys, US Inc.1$18
Coherus Oncology, Inc.1$18
Dova Pharmaceuticals1$18
E.r. Squibb & Sons, L.L.C.1$17
Melinta Therapeutics, LLC1$16
Tersera Therapeutics LLC1$16
Pharmacosmos Therapeutics Inc.1$16
Emmaus Medical, Inc.1$16
Gilead1$15
Epizyme, Inc.1$13

How this compares

$246,626 in reported general payments places this provider in the 95th percentile of 24 surgical oncology providers in Missouri.

See all surgical oncology providers in Missouri →

Medicare billing

Part B allowed, 2024
$56,051
Medicare patients
96
Services billed
154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other surgical oncology in Saint Louis

See the full list for Missouri →

Where these figures come from

Is this you, or does something look wrong? →